Hutchmed China to make several presentations at cancer research meeting

5th Apr 2024 11:54

(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer Research (AACR) annual meeting from 5 to 10 April in San Diego, California.

The AIM-traded firm said one of the highlights would be the initial preclinical data on HMPL-506, a novel and highly potent menin-MLL inhibitor developed for treating certain types of acute leukaemia.

Notably, HMPL-506 showed stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukaemia cell line models compared to five other menin inhibitors in clinical development.

Additionally, when combined with azacytidine, venetoclax, or gilteritinib, HMPL-506 synergistically improved the anti-tumour effect against MLL-rearranged leukemias, both in vitro and in vivo.

The company said the investigational drug candidate showed favourable pharmacokinetic profiles, high selectivity, and a low risk of cardiac toxicity.

It said plans were underway for a phase one study of HMPL-506 in the second half of 2024.

Another significant presentation would feature initial preclinical data on HMPL-A067 (HMA800067), a novel CD38-targeting antibody-drug conjugate (ADC) where daratumumab was conjugated with cytotoxic payload monomethyl auristatin E (MMAE) via a novel linker.

The ADC demonstrated significant superior anti-tumor activity to daratumumab, Hutchmed explained, including in several B-cell malignancies models resistant to daratumumab treatment.

Additional presentations would cover preclinical data on the ERK 1/2 inhibitor, HMPL-295; early clinical data on the Syk inhibitor, sovleplenib, in lymphoma patients; as well as further clinical data from global studies of VEGFR inhibitor, fruquintinib, and MET inhibitor, savolitinib.

Various investigator-initiated studies on fruquintinib and VEGFR/CSF-1R/FGFR inhibitor, surufatinib, would also be presented, the company added.

At 1208 BST, shares in Hutchmed China were down 2.24% at 261.01p.

Reporting by Josh White for Sharecast.com.